Salute e Benessere
Dioseve Completes Funding Round, Raising a Total of 7 Million USD
*1. The Common name for the "ASKA Innovation Investment Limited Partnership," co-managed by ASKA Pharmaceutical Co., Ltd. and Future Venture Capital Co., Ltd.
*2. The Common name for the "Hokuriku Regional Venture Investment Limited Partnership," co-managed by QR Investment Inc. (a subsidiary of Hokugin Financial Holdings Inc.) and Carbon Ventures Inc. (a subsidiary of Mitsutani Sangyo Co., Ltd.)
The Company's main pipeline is the provision of a new infertility treatment using the "DIOLs" technology. This method involves introducing specific genes into iPS cells to produce oocytes in a short period, without expensive growth factors or advanced techniques required by existing production methods, enabling oocyte production in cheap and large quantities.
Assisted reproductive technology has seen little innovation since the invention of IVF 45 years ago, and fertility largely depends on individual conditions and age. Consequently, many women face life plans based on optimal reproductive age and must choose between a career or having children. By applying this technology in assisted reproductive medicine, we aim to free couples from "not knowing if they can have children" and the constraints of optimal reproductive age, offering them the choice to become mothers at their desired time.
View original content: https://www.prnewswire.co.uk/news-releases/dioseve-completes-funding-round-raising-a-total-of-7-million-usd-302184667.html